Rofecoxib reduces polyp recurrence in familial polyposis

Area of Science:

• Gastroenterology
• Oncology
• Pharmacology

Background:

• Familial polyposis is an inherited condition characterized by numerous polyps in the colon.
• These polyps have a high risk of progressing to colorectal cancer.
• Effective long-term management strategies are crucial for preventing cancer in these patients.

Purpose of the Study:

• To evaluate the long-term efficacy and safety of rofecoxib in managing polyps in familial polyposis patients.
• To assess the drug's impact on polyp formation rate, size, and histological grade.
• To determine if rofecoxib can prevent the development of cancer or high-grade adenomas.

Main Methods:

• A prospective study involving eight familial polyposis patients treated with rofecoxib 25 mg daily.
• Regular sigmoidoscopy/colonoscopy assessments every six months for polyp evaluation and removal.
• Assessment of polyp number, size, and histological grade at baseline and throughout the follow-up period.

Main Results:

• Rofecoxib demonstrated a significant reduction in polyp formation rate (70-100%) over the study period (mean follow-up of 16.4 months).
• The mean number of polyps decreased from 15.1 at baseline to 1.6 at the end of follow-up (P = 0.008).
• No patients developed cancer or high-grade adenomas during treatment, and the drug was well-tolerated with no significant adverse events.

Conclusions:

• Long-term administration of rofecoxib is a safe and effective treatment for inhibiting polyp formation in familial polyposis.
• Rofecoxib shows promise in preventing the progression to colorectal cancer in high-risk individuals.
• COX-2 inhibitors represent a viable therapeutic option for managing familial polyposis.